LandMe

Senior Scientist, Translational Medicines & Biomarkers

Avalo Therapeutics · Chesterbrook, Pennsylvania

OnsiteDirect from the employer

Posted Oct 6, 2026 · Verified open Oct 9, 2026

Apply on the employer's siteFind more jobs like this on LandMe

About the job

At Avalo (ahh-vah'-low), we are 100% focused on developing treatments for immune-mediated inflammatory diseases with large unmet needs that affect millions worldwide. Our strategy is to develop medicines that target the IL-1β pathway, which is a central driver of the inflammatory process.

We share a commitment to teamwork, passion for science, and dedication to patients suffering from acute and chronic inflammatory disorders. Our collective expertise in discovery, development, and regulatory approvals is evidenced in our strong individual track records of advancing multiple therapeutic programs to successful commercialization.

Position Summary:

The Senior Scientist ,Translational Medicines & Biomarkers will provide scientific leadership and support across clinical and preclinical development programs.

The successful candidate will be responsible for developing and executing translational and biomarker strategies, interpreting biomarkers data integration with PK, PD, ADA, NAb, efficacy, and safety data, and supporting the advancement of clinical-stage and early pipeline programs.

This role requires a scientist who can independently analyze complex datasets, develop scientifically rigorous conclusions, and communicate actionable recommendations to multidisciplinary teams and senior leadership.

Essential Duties and Responsibilities:

Clinical biomarker and translational strategy

Clinical-data analysis and interpretation

Early pipeline Support

Cross-functional collaboration

Scientific communication

Required Education and Experience:

Preferred Qualifications

Additional Skills, Knowledge, And/or Abilities:

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1–4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com .

ATTENTION: External Agencies and Placement Firms

A member of the Avalo Human Resources Department will contact an agency directly if an open position is eligible to be sourced from an outside recruiting service. Avalo does not accept unsolicited resumes from employment agencies for any employment opportunity. All agencies/recruiters must have a written agreement/SOW in place with Avalo and prior to submitting any resume or CV.

All resumes must be submitted through the appropriate process. Any resumes submitted without an agreement and/or any resumes sent unsolicited through e-mail accounts of Avalo employees will be considered outside of the appropriate process, do not imply or create any obligation on our part, do not impart any restrictions on Avalo with respect to the hiring of any persons whose resumes are so submitted and are not eligible for placement fees.